MARKET

EVMN

EVMN

EVOMMUNE INC
NYSE
22.92
+0.20
+0.88%
After Hours: 23.00 +0.08 +0.35% 16:56 05/15 EDT
OPEN
22.19
PREV CLOSE
22.72
HIGH
23.03
LOW
22.01
VOLUME
484.10K
TURNOVER
--
52 WEEK HIGH
33.20
52 WEEK LOW
13.89
MARKET CAP
825.54M
P/E (TTM)
-35.6066
1D
5D
1M
3M
1Y
5Y
1D
Oppenheimer Sticks to Its Buy Rating for Evommune, Inc. (EVMN)
TipRanks · 1d ago
Matt Phipps Reiterates Buy on Evommune as EVO301 Data Strengthen IL‑18 Blockade Thesis and Support Blockbuster Potential
TipRanks · 1d ago
Analysts’ Top Healthcare Picks: Allogene Therapeutics (ALLO), Evommune, Inc. (EVMN)
TipRanks · 2d ago
Evommune Is Maintained at Overweight by Morgan Stanley
Dow Jones · 4d ago
Morgan Stanley Maintains Overweight on Evommune, Raises Price Target to $55
Benzinga · 4d ago
Weekly Report: what happened at EVMN last week (0504-0508)?
Weekly Report · 5d ago
Evommune (EVMN) Earnings Decline Versus 85.7% Revenue Growth Tests Bullish Narratives
Simply Wall St · 05/09 01:30
Evommune, Inc. (EVMN) Gets a Buy from RBC Capital
TipRanks · 05/08 12:45
More
About EVMN
Evommune, Inc. is a clinical-stage biotechnology company developing therapies that target key drivers of chronic inflammatory diseases. Its initial clinical development programs are focusing on chronic spontaneous urticaria (CSU), atopic dermatitis (AD) and ulcerative colitis (UC). Its product candidates include EVO756 and EVO301. The Company's advanced clinical-stage product candidate, EVO756, is a potent and highly selective oral small molecule antagonist of MRGPRX2, a receptor predominantly found on mast cells and peripheral sensory neurons, which is initially being evaluated in Phase II trials for the treatment of CSU and AD. The Company's second clinical-stage product candidate, EVO301, is a long-acting fusion protein consisting of an IL-18 binding protein (BP) and an anti-serum albumin Fab-associated (SAFA) domain, which is being evaluated in Phase II trials for the treatment of AD and UC.

Webull offers Evommune, Inc. stock information, including NYSE: EVMN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EVMN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EVMN stock methods without spending real money on the virtual paper trading platform.